Skip to content
The Policy VaultThe Policy Vault

Lorbrena (lorlatinib) — Medica

Erdheim-Chester Disease

Initial criteria

  • Patient is age ≥ 18 years
  • Patient has anaplastic lymphoma kinase (ALK) rearrangement/fusion-positive disease

Approval duration

1 year